Emedin Prevents Intrahepatic Fat Accumulation, Inflammation and Redox Status Imbalance During Diet-Induced Hepatosteatosis in Rats

Anna Alisi 1*, Anna Pastore 2, Sara Ceccarelli 1, Nadia Panera 1, Daniela Gnani 1, Giovannella Bruscalupi 3, Mara Massimi 4, Giulia Tozzi 5, Fiorella Piemonte 5 and Valerio Nobili 1

1 Liver Unit of “Bambino Gesù” Children’s Hospital, IRCCS, Rome 00165, Italy; E-Mails: sara.ceccarelli@opbg.net (S.C.); nadia.panera@opbg.net (N.P.); daniela.gnani@yahoo.it (D.G.); nobili66@yahoo.it (V.N.)
2 Laboratory of Biochemistry, of “Bambino Gesù” Children’s Hospital, IRCCS, Rome 00165, Italy; E-Mail: anna.pastore@opbg.net
3 Department of Biology and Biotechnology “C. Darwin”, “La Sapienza” University, Rome 00185, Italy; E-Mail: giovannella.bruscalupi@uniroma1.it
4 Department of Basic and Applied Biology, University of L’Aquila, L’Aquila 67010, Italy; E-Mail: mara.massimi@univaq.it
5 Neuromuscular and Neurodegenerative Disease Unit, “Bambino Gesù” Children’s Hospital, IRCCS, Rome 00165, Italy; E-Mails: giulia.tozzi@opbg.net (G.T.); fiorella.piemonte@opbg.net (F.P.)

* Author to whom correspondence should be addressed; E-Mail: anna.alisi@opbg.net; Tel.: +39-06-68592186; Fax: +39-06-68592904.

Received: 9 January 2012; in revised form: 7 February 2012 / Accepted: 9 February 2012 / Published: 20 February 2012

Abstract: High-fat and/or high-carbohydrate diets may predispose to several metabolic disturbances including liver fatty infiltration (hepatosteatosis) or be associated with necro-inflammation and fibrosis (steatohepatitis). Several studies have emphasized the hepatoprotective effect of some natural agents. In this study, we investigated the potential therapeutic effects of the treatment with emodin, an anthraquinone derivative with anti-oxidant and anti-cancer abilities, in rats developing diet-induced hepatosteatosis and steatohepatitis. Sprague-Dawley rats were fed a standard diet (SD) for 15 weeks, or a high-fat/high-fructose diet (HFD/HF). After 5 weeks, emodin was added to the drinking water of some of the SD and HFD/HF rats. The experiment ended after an additional 10 weeks. Emodin-treated HFD/HF rats were protected from hepatosteatosis and metabolic
derangements usually observed in HFD/HF animals. Furthermore, emodin exerted anti-inflammatory activity by inhibiting the HFD/HF-induced increase of tumor necrosis factor (TNF)-α. Emodin also affected the hepatocytes glutathione homeostasis and levels of the HFD/HF-induced increase of glutathionylated/phosphorylated phosphatase and tensin homolog (PTEN). In conclusion, we demonstrated that a natural agent such as emodin can prevent hepatosteatosis, preserving liver from pro-inflammatory and pro-oxidant damage caused by HFD/HF diet. These findings are promising, proposing emodin as a possible hindrance to progression of hepatosteatosis into steatohepatitis.

**Keywords:** hepatosteatosis; emodin; high fat diet; high fructose diet; redox status

1. Introduction

Hepatosteatosis or simple fatty liver is characterized by accumulation of fat in liver cells. There are several different causes of hepatosteatosis, including chronic alcohol consumption, B and C viral hepatitis, type 2 diabetes, obesity and some metabolic aberrations [1,2]. Actually, nonalcoholic fatty liver disease (NAFLD) is considered the most prevalent form of hepatosteatosis associated with obesity and metabolic syndrome [3,4]. During the last 20 years, NAFLD has reached worrying proportion involving 20–30% of adults and 3–10% of children in Western countries [5]. NAFLD genesis is multifactorial and comprises different patterns of liver injuries including simple hepatosteatosis alone or in combination with nonalcoholic steatohepatitis (NASH), with or without fibrosis [6].

In recent years, many studies have provided new insights explaining potential mechanisms responsible for the switch from hepatosteatosis to NASH. So far it has been established that NAFLD pathogenesis and progression depends on different “hits” and it has been shown that the genetic makeup and dietary intake play key roles as leading factors [7,8]. A working model [9] has been proposed consisting of two sequential “hits”, the first conducting to the hepatic steatosis and the second towards the hepatic necro-inflammation determining the NASH condition and possibly fibrosis. Firstly, the insulin resistance (IR), and/or the derangement of fatty acid metabolism (de novo lipogenesis, lower beta oxidation, impairment of triglyceride clearance and the diminished export of very-low-density lipoprotein), leads to hepatic fat accumulation and increased liver sensitivity to other possible subsequent hits [3,10]. Followed by a still largely unknown mechanism, multifactorial complex interactions have been described as responsible for the “second hit” leading to the more advanced form of NASH which can possibly predispose to cirrhosis [11,12]. This further hit includes oxidative stress, lipid peroxidation, imbalance of inflammatory cytokines and adipokines and augmentation of pathogen- or damage-associated molecular patterns [13–15].

Nowadays the intervention against the NAFLD status encompasses two different and complementary directions: lifestyle changes and/or pharmacological treatment against specific hits potentially involved in NAFLD pathogenesis (i.e., insulin resistance and oxidative stress) [16]. In the last decade many noteworthy efforts have been made for ameliorating the hepatic damage in NAFLD. It has been extensively demonstrated that metformin, vitamin E or placebo treatments do not have positive effects...
on liver injury although vitamin E is able to improve the hepatocellular ballooning degeneration [17]. The current known targets for treatment of NAFLD are limited in number and are not even sufficiently defined and a breakthrough for new tolerated and efficient compounds is needed [16]. In fact, many studies are aimed at testing the effect of natural agents on NAFLD evolution [18–25]. It has been proven that Silibinin (silybin), a polyphenolic molecule constituent of silymarin (a flavonolignan extracted from Silibum marianum), has anti-oxidant and hepatoprotective effects [20]. Moreover, it protects against cirrhosis, decreases fibrosis if complemented to vitamin E and phospholipids and decreases both insulin resistance and plasma markers of liver fibrosis in NAFLD patients [21]. Curcumin, a polyphenol and an active component of turmeric (Curcuma longa), is another natural compound investigated by several laboratories. Clinical studies showed a protective action against fructose-induced hepatic steatosis by improving inflammation, hyperlipidemia, reducing insulin resistance and interrupting leptin signaling [22–24]. Interestingly, it has been demonstrated that emodin (1,3,8-trihydroxy-6-methylanthraquinone), which is an active herbal component traditionally used in China for treating a variety of diseases, might have a role in the disease regression in NAFLD-induced rats. In fact, emodin significantly decreased the body weight, liver index, serum activities of ALT, blood lipids, hepatic triglyceride and considerably improved the hepatic histology features [25]. Despite these encouraging results, to date no further thoughtful studies have been made to understand mechanisms and reliability of emodin in NAFLD models.

The wide diffusion of NAFLD in developed countries and its close correlation with cirrhosis, place the study of both prevention and therapeutic approaches, based on natural safe and efficient agents, in a central position of interest. Thus, in this study we attempted to investigate the potential preventive properties of emodin in a diet-induced hepatosteatosis in rats.

2. Results and Discussion

2.1. Effects of Five Weeks HFD/HF Diet on Rats

Nowadays the pivotal role of fructose in NAFLD pathogenesis is widely recognized [26,27]. In fact, the excessive fructose intake may enhance the synthesis of triacylglycerols that accumulate in the liver causing hepatosteatosis, and trigger the inflammatory response that lead to NASH [28,29]. Noteworthy, recently Kohli et al. [30] developed a model of NAFLD that well resembled human disease by using an animal model fed with high-fructose medium-chain-trans-fat diet. Moreover, more recently we developed another interesting model of NAFLD that combined high fat diet with high 30% fructose-enriched drinking water [31]. In this study, we used the same high fat/high fructose (HFD/HF) dietetic regimen compared to standard diet (SD) for 5 and 15 weeks. At the end of the 5th week of treatment, SD and HFD/HF animal body weight data was recorded. At the same time, blood samples were collected from caudal vein to perform metabolic analysis. As shown in Table 1, animal body weight displayed an increase of about 19% compared to the beginning of diet protocols. However, no sign of NAFLD was already evident in HFD/HF, as shown by the absence of statistically relevant changes in body weight and metabolic parameters between the two groups of treatment. These results suggest that rats may accumulate significant traits of hepatosteatosis if the treatment with HFD/HF diet is extended for a longer period of time. In fact, as we recently demonstrated, a 3 months treatment with
HFD/HF diet is necessary to develop hepatosteatosis and NASH in Sprague-Dawley rats [31].

**Table 1.** Body weight and biochemical parameters at 5th week.

| Parameters               | SD            | HFD/HF        |
|--------------------------|---------------|---------------|
| Body weight (g)          | 140.8 ± 25.8  | 143.6 ± 23.2  |
| Triglycerides (mg/dL)    | 92 ± 13.5     | 104 ± 19.4    |
| Total cholesterol (mg/dL)| 39.5 ± 5.8    | 44.0 ± 6.2    |
| ALT (U/L)                | 22.3 ± 3.6    | 25.4 ± 4.5    |
| Glucose (mg/dL)          | 65.0 ± 7.5    | 73.4 ± 10.1   |
| Insulin (ng/mL)          | 0.23 ± 0.04   | 0.25 ± 0.03   |
| HOMA-IR                  | 0.92 ± 0.08   | 1.13 ± 0.15   |

Values are means ± SD.

2.2. Effects of Emodin on Body Weight, Liver Weight and Metabolic Parameters in HFD/HF Rats

Dong et al. [25], as reported above, demonstrated the emodin therapeutic action in Sprague-Dawley rats fed with high-caloric diet for 12 weeks. Whereas, here, we evaluated the preventive effect of emodin (40 mg/kg/day) in 5 weeks pre-treated rats that received the treatment with SD or HFD/HF for an additional 10 weeks. Data collected from these animals were compared with two groups subjected to SD or HFD/HF without addition of emodin. At the end of treatments, the body and liver weight, and liver index (liver weight/body weight × 100), were evaluated. As reported in Table 2, in HDF/HF group the weight patterns were significantly increased compared with those in the SD group ($P < 0.05$). Interestingly, in HFD/HF animals emodin treatment caused a slight increase of body weight ($P < 0.05$), that was counteracted by a significant decrease of liver weight and index ($P < 0.01$). As expected, HFD/HF diet resulted in a significant rise in plasma levels of ALT, triglycerides, insulin and glucose, and HOMA-IR ($P < 0.01$). Interestingly, emodin treatment in HFD/HF group considerably reduced metabolic parameters bringing their values at levels very similar to those observed in SD animals (see Table 2).

2.3. Hepatoprotective and Anti-Inflammatory Effects of Emodin in HFD/HF Rats

Currently, the diagnosis of NAFLD, and particularly the identification of steatohepatitis, is based on the histological evaluation of the liver biopsy [6]. Therefore, liver histology, despite its limitations, is the most reliable method to assess grading and staging of all histological features that characterize NASH both in humans and animal models [32,33]. Here, we analyzed the histological pattern of NAFLD by Hematoxylin-Eosin (H-E) staining. Liver of HFD/HF animals showed typical microvacuolar and macrovacuolar steatosis, ballooning, and some inflammatory cells, confirming the successful establishment of the animal model. With the emodin treatment HFD/HF animals displayed reduced cytological steatosis and ballooning, and a complete absence of inflammatory cells (Figure 1). These results are in agreement with previous studies demonstrating the hepatoprotective role of emodin both in the case of hepatosteatosis and in other liver diseases [34–36]. Emodin exerts multiple effects, including anti-proliferative, anti-cancer, anti-inflammatory and hepatoprotective activities [37–39].
Emodin has also been reported to reduce serum hyaluronic acid, laminin expression, hepatic levels of hydroxyproline and the degree of liver fibrosis [40].

Table 2. Body weight and biochemical parameters after emodin treatments for 10 weeks.

| Parameters                | SD                  | HFD/HF              | SD+emodin            | HFD/HF+emodin         |
|---------------------------|---------------------|---------------------|----------------------|-----------------------|
| Body weight (g)           | 295.6 ± 34.2        | 355.6 ± 28.7 *      | 308.1 ± 30.5         | 393.6 ± 31.4 †        |
| Liver weight (g)          | 11.2 ± 1.3          | 15.2 ± 1.5 *        | 12.0 ± 0.5           | 12.4 ± 0.9 †          |
| Liver weight/Body weight  | 3.7 ± 0.11          | 4.27 ± 0.09 *       | 3.8 ± 0.19           | 3.2 ± 0.2 ‡           |
| Triglycerides (mg/dL)     | 105.1 ± 18.6        | 138.0 ± 16.3 **     | 110.4 ± 13.1         | 109.4 ± 15.7 ‡        |
| Total cholesterol (mg/dL) | 45.7 ± 7.2          | 48.5 ± 8.1          | 39.9 ± 10.2          | 48.0 ± 12.3           |
| ALT (U/L)                 | 25.2 ± 5.0          | 37.4 ± 3.9 **       | 26.0 ± 4.4           | 25.9 ± 5.8 ‡          |
| Glucose (mg/dL)           | 69.4 ± 4.4          | 81.9 ± 5.7 **       | 68.3 ± 7.2           | 70.8 ± 9.6 ‡          |
| Insulin (ng/mL)           | 0.24 ± 0.05         | 0.41 ± 0.09 **      | 0.25 ± 0.07          | 0.26 ± 0.03 ‡         |
| HOMA-IR                   | 1.02 ± 0.05         | 2.07 ± 0.18 **      | 1.05 ± 0.06          | 1.13 ± 0.19 ‡         |

Values are means ± SD. * P = 0.05, ** P < 0.01, vs. SD group; Values are means ± SD. † P = 0.05, ‡ P < 0.01, vs. HFD/HF group.

Figure 1. Histological changes of rat liver in each group stained by H-E (Magnification 200×).

In this, study we also evaluated the systemic anti-inflammatory properties of emodin by the analysis of plasma levels of two relevant pro-inflammatory cytokines in NAFLD, tumor necrosis factor (TNF)-α and interleukin 6 (IL6) [41]. Although, the increased hepatic expression of TNF-α and IL6 has been described in NAFLD obese patients, changes and significance of the circulating levels of these cytokines still remain unclear [42,43]. Recently, it has been demonstrated that either high carbohydrate diet or high fat diet are able to increase plasma levels of TNF-α in mice [44]. In the present study, we examined the circulating levels of TNF-α and IL6 in all animal groups. As reported in Figure 2a and b, HFD/HF regimen induced a significant increase in the plasma levels of TNF-α with respect to the SD; whereas no significant differences in the IL6 plasma levels were found between the two groups. Interestingly, the treatment with emodin impeded the rise of plasma TNF-α, maintaining this circulating cytokine at levels similar to those observed in SD group.

Anti-inflammatory activity of emodin has already been reported, but this study represents the first evidence demonstrating its potential preventive action on systemic inflammation occurring in NAFLD.
Figure 2. Plasma levels of TNF-α (a) and IL6 (b) in all groups of treatment. Values are means ± SD. *** P < 0.001, vs. SD group. ‡ P < 0.01, vs. HFD/HF group.

2.4. Emodin Promotes Recovery of Redox Status Imbalance in Primary Hepatocytes from HFD/HF Rats

Glutathione is a tripeptide that exists in a reduced (GSH) and oxidized form (GSSG). The ratio between these two glutathione forms is fundamental for maintaining the redox status balance and important cellular functions, such as cell proliferation [45]. GSSG may also occur as protein-bound glutathione (ProSSG). ProSSG plays a pivotal role in the regulation of important regulatory proteins including NFκB and PTEN (glutathionylation) [46,47]. We recently demonstrated that HFD/HF diet was able to promote redox status imbalance particularly increasing the ratio between ProSSG and total GSH (Tot GSH = GSSG + GSH + ProSSG) in primary hepatocytes [48]. Here we confirmed this data and demonstrated that emodin treatment protects from the increment of ProSSG/Tot GSH ratio in primary hepatocytes isolated from HFD/HF (Figure 3a). These results corroborate the hypothesis of a strong anti-oxidant action of emodin on steatotic livers. Moreover, as in the previous published study [48], we found that HFD/HF diet caused an increment in phosphorylation/glutathionylation of hepatic PTEN, that is consistent with the inhibition of its activity; here we assayed if emodin was able to protect primary hepatocytes from PTEN phosphorylation/glutathionylation. As reported in Figure 3b, emodin treatment preserves PTEN either from phosphorylation and glutathionylation.

A quantity of data has shown that the alterations of PTEN expression and activity are related with liver disorders and its deregulation plays a key role both in hepatic insulin sensitivity and the onset of steatosis, steatohepatitis and fibrosis [49]. Moreover PTEN regulates the PI3K/Akt signaling pathways [50] and Akt is differently involved in glucose homeostasis and diabetes [51]. In this study we have demonstrated that the increased PTEN phosphorylation/glutathionylation in HFD/HF diet rats may be counteracted by emodin treatment. The significance of these results is intriguing since the recovery of PTEN activation should explain the improved effect on insulin resistance in emodin-treated HFD/HF rats. Therefore, in the future, it would be interesting to study the activity of PTEN before and after the emodin treatment. Moreover, it would be worth investigating a possible Akt role in the mechanism regulating the positive effect of emodin with regard to the disrupted glucose homeostasis in NAFLD rat model.
Figure 3. (a) ProSSG/Tot GSH ratios were reported. Histograms are the mean value ± S.D. *** $P < 0.001$, vs. SD group. ‡ $P < 0.01$, vs. HFD/HF group; (b) Western blotting of total, phosphorylated and glutathionylated PTEN in primary hepatocytes isolated from livers of each group of treatment.

2.5. Emodin Protects HFD/HF Primary Hepatocytes Rats from Further Oxidative Stress Damage

Hepatosteatosis may evolve to NASH with fibrosis that destructs liver tissue integrity and cell homeostasis. This phenomenon occurs by a pool of secondary hits, among which the most relevant is the oxidative stress [13]. Our hypothesis is that preventive treatment with emodin not only may protect HFD/HF rats from hepatosteatosis, but it may also induce an anti-oxidant stable reaction of hepatocytes against further oxidative stress damage and predispose liver cells to a better response to additional anti-oxidant conventional drugs (e.g., N-acetylcysteine and α-tocopherol). To assess this hypothesis, we isolated primary hepatocytes from rats treated with SD, or HFD/HF regimen with or without emodin. These cells were cultured for 24 h in the presence or the absence of the following treatments: 500 µM hydrogen peroxide (H$_2$O$_2$) or 1 mM N-acetylcysteine (NAC). At the end of the experiment, we collected cells to evaluate ProSSG/Tot GSH ratio and cell viability. As shown in Figure 4a, the treatment with H$_2$O$_2$ dramatically increased ProSSG/Tot GSH ratio in hepatocytes from HFD/HF rats, but this effect was significantly reduced in hepatocytes from emodin-treated HFD/HF animals. On the other hand, in hepatocytes from HFD/HF rats, the treatment with NAC caused a relevant decrease of ProSSG/Tot GSH ratio that was enhanced by the concomitant presence of emodin in animals’ in vivo treatment.

Finally, cell viability results indicated that hepatocytes from HFD/HF animals displayed a reduced cell viability, after 24 h culture, compared with SD-derived hepatocytes (Figure 4b). However, in hepatocytes from HFD/HF, this reduced viability was significantly counteracted by NAC treatment and retrieved even more if the hepatocytes were derived from emodin treated HFD/HF rats as described above.

Altogether, these findings indicate that HFD/HF regimen may profoundly alter oxidative stress response and cell homeostasis of hepatocytes, but these effects are counteracted by the preventive treatment with emodin.
Figure 4. (a) ProSSG/Tot GSH ratios were reported as fold induction; (b) Cell viability at 24 h was evaluated by a neutral red assay and reported as percentage compared with the control (SD). Histograms are the mean value ± S.D. *** P < 0.001; ‡ and § P < 0.01, # P < 0.05.

3. Experimental Section

3.1. Animals and Primary Hepatocytes

Twenty-four male Sprague–Dawley rats (120–140 g) were obtained from Harlan Italy (San Pietro al Natisone, UD, Italy). The animals received treatment in agreement with the European guidelines of the local committee for animal care and welfare. The animals used in this study were part of a large experimental protocol approved by Italian Ministry of Health. They were located in plastic cages under standard conditions with free access to water and food, at the Certified Animal Facility of the University of Rome, “La Sapienza”. The animals were fed with standard rat chow for 5 days then equally grouped based on two different dietetic regimens: a standard diet (SD) and a high-fat/high-fructose diet (HFD/HF). SD contained 5% of energy derived from fat, 18% from proteins, and 77% from
carbohydrates (3.3 kcal/g), while HFD/HF contained 58% of energy derived from fat, 18% from protein, and 24% from carbohydrates (5.6 kcal/g; Laboratorio Dottori Piccioni, Gessate Milano, Italy); plus fructose (30%) that was added to the drinking water. After 5 weeks half of SD and HFD/HF were treated with emodin (40 mg/kg/day) from Sigma-Aldrich, Milan, Italy. Fluid and food intake were assessed every two-days at the replacement. We found no significant differences between consumption of food and water among the groups.

Randomly after 6 h fasting, from each group of animal, liver tissues were taken for biochemistry and histology. Further, from each group primary hepatocytes have been isolated using a perfusive method as previously described [52]. Briefly, the rats were anesthetized by intraperitoneal administration of sodium pentobarbital (5 mg/100 g body weight). The liver was perfused firstly with a calcium-free Hank’s balanced salt solution containing 2% BSA and 0.6 mM ethyleneglycoltetraacetic acid, and secondly with Hank’s solution containing 4 mM calcium chloride and 0.04% collagenase. Liver cells were released into a Krebs–Henseleit buffer with 2% BSA. The hepatocytes were seeded on collagen-coated plates at density between 1.5 × 10^4 and 3 × 10^4 /cm^2. After 24 h from plating hepatocytes from SD, HFD/FD, SD + Emodin, HFD/HF + Emodin animals were subjected to following treatments: 10 μL PBS (NT) or N-acetylcysteine 1mM (NAC) or H2O2 500μM (H2O2). Hepatocytes were harvested 24 h later, centrifuged and collected for the experiments.

3.2. Biochemical Determinations and Inflammatory Markers

Blood samples obtained from caudal vein after 6 h fasting were collected in sterile glass tubes containing 0.15% EDTA. Blood samples were centrifuged at 3000 for 15 min to obtain plasma. Plasma samples were immediately used to perform enzymatic and colorimetric assay to determine the levels of alanine aminotransferase (ALT), triglycerides, total cholesterol, glucose and insulin. Enzymatic and colorimetric assays were performed using standard procedures as indicated by kits purchased from different companies: ALT assay kit from Randox Laboratories Ltd (Antrim, UK), triglycerides and cholesterol assay kits from Cayman Chemical (Ann Arbor, MI, USA), glucose assay kit from Abcam Inc (Cambridge, MA, USA), and rat insulin enzyme immunoassay kit from SPI-BIO (France). At 14 weeks, insulin resistance was calculated according to the homeostasis model assessment of insulin resistance (HOMA-IR) calculation: fasting plasma insulin (μU/mL) × fasting plasma glucose (mmol/L)/22.5. ELISA-based kits were used to assay the circulating levels TNF-α (Peprotech, Rocky Hill, New Jersey, USA) and IL6 (R&D Systems, Abingdon, UK).

3.3. Immunohistochemistry

Liver was fixed in 4% buffered formalin and embedded in paraffin. A measure of 3–5 μm sections were stained with haematoxylin and eosin (Bio-Optica, Milan, Italy). Then the specimens were evaluated under 10 × 20 light microscopic fields.

3.4. High-Performance Liquid Chromatography of GSH

The tissues and primary hepatocytes from liver mouse model NASH diet-induced or NASH diet-induced treated with Emodin were sonicated (Sonics Vibra Cell, Sonics & Material Inc., Newtown,
CT, USA), three times for 2 s in 0.1 mL of 0.1 M potassium phosphate buffer (pH 7.2). Following the sonication levels of total (GSH Tot), reduced (GSH), oxidized (GSSG) and protein-bound (ProSSG) glutathione were analyzed by HPLC. HPLC equipment and conditions for analyzing the several forms of glutathione have been reported [53].

3.5. Immunoprecipitation and Western Blotting

Liver tissues were lysed in ice-cold Ripa buffer containing 50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EGTA, 1% sodium deoxycholate and phosphatases 10% cocktail protease inhibitors. For the immunoprecipitation protocol of the glutathionylated proteins see previous published work [46]. Then protein extracts were resolved on 10–12.5% SDS-PAGE, transferred and immobilized onto nitrocellulose membrane (Amersham, Germany), blocked with 5% nonfat dry milk and incubated with appropriate primary and secondary antibodies. The anti-PTEN, anti-pPTEN, primary antibodies were purchased from Santa Cruz Biotech (CA, USA). Immunoblots were detected with the ECL system (Amersham) and the relative intensities of the specific bands were determined by densitometric analysis and referring to beta-actin protein expression.

3.6. Cell Viability

Cell viability was determined by a simple vital stain method that evaluates the accumulation of the neutral red dye in the lysosomes of viable, uninjured cells [54]. The simple vital Neutral red (Sigma-Aldrich) was dissolved in culture medium and added to cells for 1 h. The pH of the neutral red solution was adjusted in all the experiments to 6.35 with the addition of 1 M KH₂PO₄. Then, cells were washed thrice with PBS, and 1 mL of elution medium (EtOH/AcCOOH, 50%/1%) was added followed by gentle shaking for about 10 minutes to obtain the complete dissolution. Measures were acquired with spectrophotometer at 540-nm of absorbance.

3.7. Statistical Analysis

The results are reported as means ± SD. for at least four independent experiments. Statistical differences were determined by Student’s t test considering \( P < 0.05 \) as statistically significant.

4. Conclusions

In summary, in this study we reported for the first time the preventive effect of emodin on hepatosteatosis-dependent metabolic derangement and liver cell injury. In particular, our results demonstrated that emodin was able to protect rats, treated with high fat/high fructose diet, from insulin resistance, hypertriglyceridaemia, histological damage, systemic necro-inflammation, and oxidative stress. Furthermore, interestingly, we demonstrated that emodin treatment conferred to HFD/HF hepatocytes an important defense from additional oxidative stress, and an improved ability to react to classical anti-oxidant agents. Our data suggested that PTEN could be a target of emodin, but the full comprehension of the existing molecular mechanisms of this natural agent requires further study.
In conclusion, all these findings suggest the use of emodin, not only as a potential preventive agent in NAFLD diet-induced and a promising agent for hampering the progression to NASH, but also as a natural coadjuvant of the more classical antioxidant therapy.

Conflicts of Interest

No conflict of interest exists.

References

1. Mantena, S.K.; King, A.L.; Andringa, K.K., Eccleston, H.B.; Bailey, S.M. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. *Free Radical Biol. Med.* 2008, 44, 1259–1272.
2. Clément, S.; Negro, F. Hepatitis C virus: The viral way to fatty liver. *J. Hepatol.* 2007, 46, 985–987.
3. Wree, A.; Kahraman, A.; Gerken, G.; Canbay, A. Obesity affects the liver—the link between adipocytes and hepatocytes. *Digestion* 2011, 83, 124–133.
4. Khashab, M.A.; Liangpunsakul, S.; Chalasani, N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. *Curr. Gastroenterol. Rep.* 2008, 10, 73–80.
5. Alisi, A.; Feldstein, A.E.; Villani, A.; Raponi, M.; Nobili, V. Nonalcoholic fatty liver disease: A multidisciplinary approach. *Nat. Rev. Gastroenterol. Hepatol.* 2012, in press.
6. Brunt, E.M. Pathology of nonalcoholic fatty liver disease. *Nat. Rev. Gastroenterol. Hepatol.* 2010, 7, 195–203.
7. Feldstein, A.E. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. *Semin. Liver Dis.* 2010, 30, 391–401.
8. Moore, J.B. Non-alcoholic fatty liver disease: The hepatic consequence of obesity and the metabolic syndrome. *Proc. Nutr. Soc.* 2010, 69, 211–220.
9. Day, C.P.; James, O.F. Steatohepatitis: a tale of two “hits”? *Gastroenterology* 1998, 114, 842–845.
10. Bugianesi, E.; Mosciatiello, S.; Ciavarella, M.F.; Marchesini, G. Insulin resistance in nonalcoholic fatty liver disease. *Curr. Pharm. Des.* 2010, 16, 1941–1951.
11. Feldstein, A.E.; Charatcharoenwitthaya, P.; Treeprasertsuk, S.; Benson, J.T.; Enders, F.B.; Angulo, P. The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. *Gut* 2009, 58, 1538–1544.
12. Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Human fatty liver disease: Old questions and new insights. *Science* 2011, 332, 1519–1523.
13. Albano, E.; Mottaran, E.; Occhino, G.; Reale, E.; Vidali, M. Review article: Role of oxidative stress in the progression of non-alcoholic steatosis. *Aliment. Pharmacol. Ther.* 2005, 22, 71–73.
14. Tarantino, G.; Savastano, S.; Colao, A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. *World J. Gastroenterol.* 2010, 16, 4773–4783.
15. Alisi, A.; Carsetti, R.; Nobili, V. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. *Hepatology* 2011, 54, 1500–1502.
16. Alisi, A.; Nobili, V. Nonalcoholic fatty liver disease: Targeted therapy in children—what is the right way? *Nat. Rev. Gastroenterol. Hepatol.* 2011, 8, 425–426.
17. Lavine, J.E.; Schwimmer, J.B.; Van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N.; et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011, 305, 1659–1668.

18. Pradeep, K.; Mohan, C.V.; Gobianand, K.; Karthikeyan, S. Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. *Eur. J. Pharmacol.* 2007, 560, 110–116.

19. Comar, K.M.; Kirby, D.F. Herbal remedies in gastroenterology. *J. Clin. Gastroenterol.* 2005, 39, 457–468.

20. Di Sario, A.; Bendia, E.; Taffetani, S.; Omenetti, A.; Candelaresi, C.; Marzioni, M.; De Minicis, S.; Benedetti, A. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. *Dig. Liver Dis.* 2005, 37, 869–876.

21. Loguercio, C.; Federico, A.; Trappoliere, M.; Tuccillo, C.; de Sio, I.; Di Leva, A.; Niosi, M.; D’Aura, M.V.; Papasso, R.; Del Vecchio Blanco, C. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. *Dig. Dis. Sci.* 2007, 52, 2387–2395.

22. Shapiro, H.; Bruck, R. Therapeutic potential of curcumin in non-alcoholic steatohepatitis. *Nutr. Res. Rev.* 2005, 18, 212–221.

23. Jang, E.M.; Choi, M.S.; Jung, U.J.; Kim, M.J.; Kim, H.J.; Jeon, S.M.; Shin, S.K.; Seong, C.N.; Lee, M.K. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. *Metabolism* 2008, 57, 1576–1583.

24. Tang, Y.; Zheng, S.; Chen, A. Curcumin eliminates leptin’s effects on hepatic stellate cell activation via interrupting leptin signaling. *Endocrinology* 2009, 150, 3011–3020.

25. Dong, H.; Lu, F.E.; Gao, Z.Q.; Xu, L.J.; Wang, K.F.; Zou, X. Effèces of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw. *World J. Gastroenterol.* 2005, 11, 1339–1344.

26. Samuel, V.T. Fructose induced lipogenesis: From sugar to fat to insulin resistance. *Trends Endocrinol. Metab.* 2011, 22, 60–65.

27. Lim, J.S.; Mietus-Snyder, M.; Valente, A.; Schwarz, J.M.; Lustig, R.H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. *Nat. Rev. Gastroenterol. Hepatol.* 2010, 7, 251–264.

28. Spruss, A.; Bergheim, I. Dietary fructose and intestinal barrier: Potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. *J. Nutr. Biochem.* 2009, 20, 657–662.

29. Alisi, A.; Manco, M.; Pezzullo, M.; Nobili, V. Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis. *Hepatology* 2011, 53, 372–373.

30. Kohli, R.; Kirby, M.; Xanthakos, S.A.; Softic, S.; Feldstein, A.E.; Saxena, V.; Tang, P.H.; Miles, L.; Miles, M.V.; Balistreri, W.F.; et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. *Hepatology* 2010, 52, 934–944.
31. Alisi, A.; Da Sacco, L.; Bruscalupi, G.; Piemonte, F.; Panera, N.; De Vito, R.; Leoni, S.; Bottazzo, G.F.; Masotti, A.; Nobili, V. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. *Lab. Invest.* **2011**, *91*, 283–293.

32. Tiniakos, D.G. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Histological diagnostic criteria and scoring systems. *Eur. J. Gastroenterol. Hepatol.* **2010**, *22*, 643–650.

33. Hebbard, L.; George, J. Animal models of nonalcoholic fatty liver disease. *Nat. Rev. Gastroenterol. Hepatol.* **2011**, *8*, 35–44.

34. Lin, C.C.; Chang, C.H.; Yang, J.J.; Namba, T.; Hattori, M. Hepatoprotective effects of emodin from Ventilago leiocarpa. *J. Ethnopharmacol.* **1996**, *52*, 107–111.

35. Dong, M.X.; Jia, Y.; Zhang, Y.B.; Li, C.C.; Geng, Y.T.; Zhou, L.; Li, X.Y.; Liu, J.C.; Niu, Y.C. Emodin protects rat liver from CCI(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation. *World J. Gastroenterol.* **2009**, *15*, 4753–4762.

36. Zhao, Y.L.; Wang, J.B.; Zhou, G.D.; Shan, L.M.; Xiao, X.H. Investigations of free anthraquinones from rhubarb against α-naphthylisothiocyanate-induced cholestatic liver injury in rats. *Basic Clin. Pharmacol. Toxicol.* **2009**, *104*, 463–469.

37. Srinivas, G.; Anto, R.J.; Srinivas, P.; Vidhyalakshmi, S.; Senan, V.P.; Karunagaran, D. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. *Eur. J. Pharmacol.* **2003**, *473*, 117–125.

38. Ding, Y.; Zhao, L.; Mei, H.; Zhang, S.L.; Huang, Z.H.; Duan, Y.Y.; Ye, P. Exploration of Emodin to treat α-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway. *Eur. J. Pharmacol.* **2008**, *590*, 377–386.

39. Hsu, C.M.; Hsu, Y.A.; Tsai, Y.; Shieh, F.K.; Huang, S.H.; Wan, L.; Tsai, F.J. Emodin inhibits the growth of hepatoma cells: finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells. *Biochem. Biophys. Res. Commun.* **2010**, *392*, 473–478.

40. Zhan, Y.; Li, D.; Wei, H.; Wang, Z.; Huang, X.; Xu, Q.; Lu, H. Emodin on hepatic fibrosis in rats. *Chin. Med. J.* **2000**, *113*, 599–601.

41. Tilg, H. The role of cytokines in non-alcoholic fatty liver disease. *Dig. Dis.* **2010**, *28*, 179–185.

42. Tetri, L.H.; Basaranoglu, M.; Brunt, E.M.; Yerian, L.M.; Neuschwander-Tetri, B.A. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2008**, *295*, G987–G995.

43. Bertola, A.; Bonnafous, S.; Anty, R.; Patouraux, S.; Saint-Paul, M.C.; Iannelli, A.; Gugenheim, J.; Barr, J.; Mato, J.M.; Le Marchand-Brustel, Y.; et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. *PLoS One* **2010**, *5*, e13577.

44. Ferreira, A.V.; Mario, E.G.; Porto, L.C.; Andrade, S.P.; Botion, L.M. High-carbohydrate diet selectively induces tumor necrosis factor-α production in mice liver. *Inflammation* **2011**, *34*, 139–145.

45. Han, D.; Hanawa, N.; Saberi, B.; Kaplowitz, N. Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2006**, *291*, G1–G7.
46. Alisi, A.; Piemonte, F.; Pastore, A.; Panera, N.; Passatelli, C.; Tozzi, G.; Petrini, S.; Pietrobattista, A.; Bottazzo, G.F.; Nobili, V. Glutathionylation of p65NF-kappaB correlates with proliferating/apoptotic hepatoma cells exposed to pro- and anti-oxidants. *Int. J. Mol. Med.* **2009**, *24*, 319–326.

47. Yu, C.X.; Li, S.; Whorton, A.R. Redox regulation of PTEN by S-nitrosothiols. *Mol. Pharmacol.* **2005**, *68*, 847–854.

48. Alisi, A.; Bruscalupi, G.; Pastore, A.; Petrini, S.; Panera, N.; Massimi, M.; Tozzi, G.; Leoni, S.; Piemonte, F.; Nobili, V. Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis. *J. Nutr. Biochem.* **2012**, *23*, 169–178.

49. Peyrou, M.; Bourgoin, L.; Foti, M. PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer. *Dig. Dis.* **2010**, *1*, 236–246.

50. Vinciguerra, M.; Foti, M. PTEN at the crossroad of metabolic diseases and cancer in the liver. *Ann. Hepatol.* **2008**, *7*, 192–199.

51. Hay, N. Akt isoforms and glucose homeostasis - the leptin connection. *Trends Endocrinol. Metab.* **2011**, *22*, 66–73.

52. Leoni, S.; Spagnuolo, S.; Massimi, M.; Terenzi, F.; Conti Devirgiliis, L. Amino acid uptake regulation by cell growth in cultured hepatocytes isolated from fetal and adult rats. *Biosci. Rep.* **1992**, *12*, 135–141.

53. Pastore, A.; Federici, G.; Bertini, E.; Piemonte, F. Analysis of glutathione: implication in redox and detoxification. *Clin. Chim. Acta* **2003**, *333*, 19–39.

54. Babich, H.; Borenfreund, E. Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay. *Appl. Environ. Microbiol.* **1991**, *57*, 2101–2103.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).